Siegfried has inaugurated its global R&D center in Evionnaz

Siegfried, a prominent Swiss Contract Development and Manufacturing Organization (CDMO), has unveiled its new global Research and Development (R&D) center at its site in Evionnaz, in the canton of Valais.

Siegfried, a global leader in pharmaceutical development and manufacturing, has inaugurated a cutting-edge Research and Development (R&D) center at its Evionnaz site in the canton of Valais. This new facility, part of Siegfried’s strategic EVOLVE+ initiative, underscores the company’s commitment to advancing innovation in active pharmaceutical ingredients (APIs) and drug development while creating new opportunities within Switzerland’s thriving life sciences ecosystem.

The 4,500-square-meter R&D center is equipped with cutting-edge chemical and analytical facilities, flow chemistry technologies, advanced distillation systems, and process analytical tools. Alongside its R&D center in Zofingen, this facility will support Siegfried’s global Drug Substances network by enhancing chemical process and analytical development capabilities for phases II and III of drug development. With capacity for over 100 highly skilled professionals and the creation of 40 new positions, the Evionnaz site represents a significant boost to the company’s expertise and capacity under its EVOLVE+ strategy.

Speaking about the new facility, Marcel Imwinkelried, CEO of Siegfried, said: “The new R&D center in Evionnaz significantly strengthens our Drug Substances network and demonstrates our unwavering commitment to delivering cutting-edge research and development capabilities for our customers. It is a key element in driving development excellence as part of our EVOLVE+ strategy.”

Evionnaz has been a cornerstone of Siegfried’s operations since 2015, and the decision to expand in Valais reflects the region’s strategic advantages. The canton is known for its thriving life sciences ecosystem, skilled workforce, and strong infrastructure, making it an ideal location for the new R&D center. Its proximity to leading research institutions further enhances collaboration opportunities, enabling Siegfried to maintain its competitive edge in pharmaceutical innovation.

The new R&D center represents a critical step in Siegfried’s growth strategy, cementing its position as a leader in the CDMO sector. Specializing in active pharmaceutical ingredients and finished dosage forms, Siegfried reported CHF 1.229 billion in sales in 2022 and operates across 11 sites on three continents.